

## **‘Shorter Recovery Time in Concussed Elite Ice Hockey Players by Early Head-and-Neck Cooling’ study ranks in the Top 3 of most downloaded articles in the Journal of Neurotrauma in 2022**

**Med-tech company PolarCool AB (publ) is thrilled to announce that the groundbreaking Swedish Hockey League (SHL) study that evaluated the efficacy of the PolarCap® System in treating concussed athletes has been recognized as one of the three most downloaded publications among the >200 articles published in the prestigious Journal of Neurotrauma in 2022.**

PolarCool develops and markets the PolarCap® System, a product that alleviates the effects of concussion injuries. PolarCap® is primarily used by sports organizations and facilities in contact sports such as ice hockey, rugby, football, and handball, as well as in sports with an increased risk of concussion.

The remarkable level of interest in the study is evident from the statistics provided by the Journal of Neurotrauma, which highlight its exceptional performance as one of the top three most downloaded articles during 2022. This recognition further underscores the widespread appeal and significance of the publication within the scientific and medical communities.

Responsible researcher for the study, Professor Niklas Marklund, comments;

*- Most people are well aware that sports-related concussions pose a large health problem and that the need for improved treatment is large. We are pleased to note the great interest from the sports community, and from researchers in the field, on our study. The results are truly promising, and no adverse events were noted by the treatment applied at ca 10 minutes after concussion onset.*

This achievement marks a significant milestone for the company, as it reflects the growing interest and recognition garnered by the 5-year clinical study, which focused on the acute concussion treatment with the PolarCap® System and was published in the Journal of Neurotrauma in October 2022.

PolarCool's CEO, Erik Andersson comments;

*- We notice a great interest in PolarCap® and in the clinical study. The clinical evidence is central to our business as we realized that this has been in demand from medical decision makers. The published article in the Journal of Neurotrauma has therefore been very important in our ongoing establishment of PolarCap® in Europe.*

The study, titled "Shorter recovery time in concussed elite ice hockey players by early head-and-neck cooling – a clinical trial", was the result of a collaboration between Lund University and the Swedish Hockey League (SHL). By comparing players with concussions who were either treated with the PolarCap® System or received standard concussion treatment, the study involved a total of 19 professional hockey teams from the SHL and HockeyAllsvenskan. Notably, the research encompassed 132 cases of confirmed concussions, with 61 of them receiving treatment with PolarCap®. Among all favorable effects observed,

the most positive finding was the significant reduced risk of long-term absence among players who underwent treatment.

**For more information**

Erik Andersson – CEO

+46 – 73 860 57 00

E-mail: [erik.andersson@polarcool.se](mailto:erik.andersson@polarcool.se)

**About PolarCool AB (publ)**

*PolarCool AB (publ) is a medical device company that develops, markets, and sells products for sports medicine. The company focuses on treatment of concussive and sub-concussive brain injury with the portable cooling device PolarCap® System. PolarCool AB (publ) is based in Lund, Sweden, and its shares are listed on Spotlight Stock Market.*